Clinical stage biotechnology firm Riboscience has landed a substantial $146.8M in Series A funding, signaling continued investor confidence in the fight against serious infectious diseases and cancer. The capital infusion marks a significant milestone for the company as it advances its drug discovery pipeline.
Riboscience specializes in applying ribose and structure-guided design technologies. Its approach targets proteins essential and unique to specific infectious pathogens, tumor cells, or the anti-tumor immune response, aiming to develop novel treatments for these challenging conditions.
.png&w=3840&q=75)
